Pfizer reported Q1 2026 revenue of $14.5 billion, up 2%, reaffirming 2026 guidance of $59.5-$62.5 billion.
Legal settlements delay Vyndamax generics to 2031 (from 2028), securing a $6 billion product and enabling high single-digit revenue growth from 2029 for five years.
Settlements provide $7 billion for acquisitions, offsetting prior $17 billion LOE risk by 2030.
Acquisitions like Metsera, Seagen, and Biohaven show 22% growth.
Launched obesity drug Severwin in China via Sciwind partnership, targeting international expansion.